Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRC07-523LS in healthy HIV-uninfected adults
NCT03735849Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2019
- Primary completion
- Dec 2020
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VRC07-523LS in human immunodeficiency virus infection (HIV) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants Reporting Local Reactogenicity Signs and Symptoms, Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms and 6 more. Started Jan 2019; status: completed.
02
Drugs
VRC07-523LS
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03735849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03735849.